Right now only in mice. At least when you read about research into Alzheimers you can see hints of progress. In stroke I never see hints of progress.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=158116&CultureCode=en
Experiments by Heidelberg researchers provide insight into novel gene therapy approach to treat Alzheimer’s
In laboratory experiments on the basic mechanisms that cause
Alzheimer’s dementia, an international research team led by Heidelberg
neurobiologist Prof. Dr. Ulrike Müller and a team of French scientists
have succeeded in largely “repairing” the nerve cell damage typical in
this disease. The researchers took a closer look at a key protein in
Alzheimer’s pathogenisis, APP, and one of its cleavage products APPsα.
Prof. Müller of Heidelberg University’s Institute of Pharmacy and
Molecular Biotechnology explains that viral gene shuttles were used to
drive the delivery of APPsα into the brains of Alzheimer´s mouse models.
The protein APPsα in turn elicited repair effects and clearly improved
memory. The researchers hope to use these findings to explore new
approaches in the development of gene therapy for Alzheimer’s. Their
results were published in the journal “Acta Neuropathologica”.
Alzheimer’s is the most frequent cause of dementia in the elderly. It
particularly affects regions of the brain that are fundamental for
memory and learning. The junctions through which the nerve cells
communicate, the synapses, disappear long before the nerve cells die,
damage that impairs both learning and memory. “While dead nerve cells
are irretrievably lost, damaged synapses can be regenerated in the
elderly,” Prof. Müller emphasises.
The brains of Alzheimer’s patients show plaque deposits, she
explains. The deposits thwart the communication between the nerve cells
and cause them to eventually die. The main component of the plaque is a
short protein fragment known as the beta amyloid peptide. It is
generated when the considerably larger amyloid precursor protein, or
APP, is cleaved. “Until now, scientists believed that the overproduction
of beta amyloid peptides was the main cause of Alzheimer’s. More recent
investigations, however, have demonstrated that another APP cleavage
product, the APPsα protein, also diminishes over the course of the
disease,” Ulrike Müller continues. The protein cleaving enzymes, called
secretases, play a key role in this process. The scissor-like secretases
cut the APP cell surface protein at various positions. “These cleaving
processes produce beta amyloid peptides that are toxic to the nerve
cells, but also produce the protective APPsα cleavage product, which
counteracts the toxic peptide,” says Prof. Müller. “Research over the
last few years indicates that a misregulation of the secretase cleavage
in Alzheimer’s results in inadequate production of protective APPsα.”
Earlier studies by Müller’s research group had already shown that
APPsα has an essential function in the nervous system, particularly
because it regulates the formation and function of synaptic junctions
and spatial memory. These findings were used to investigate a new
approach for a possible gene therapy for Alzheimer’s. The international
research team used viral gene shuttles to introduce APPsα into the
brains of mouse models with plaque deposits like those in Alzheimer’s.
“After introducing the APPsα, we saw that the nerve cell damage could be
repaired. The number of synaptic junctions increased, and spatial
memory began to function again,” reports Ulrike Müller. “Our research
results show the therapeutic effectiveness of APPsα in the animal model
and open up new perspectives for the treatment of Alzheimer’s.”
The research was conducted by the international ERA-NET NEURON
Consortium, which is funded by the European Union. Other participants in
the project include the research teams of Prof. Dr. Nathalie Cartier
(University of Paris), Prof. Dr. Martin Korte (Braunschweig Technical
University) and Prof. Dr. Christian Buchholz (Paul Ehrlich Institute,
Langen).
No comments:
Post a Comment